Neuroinflammation is now recognised as an important contributory factor in the progression of Alzheimer’s disease and probably also in the early stages of the disease. It is likely that this derives largely from aberrant activation of microglia, the resident mononuclear phagocytes of the brain. These cells are responsible for physiological immune surveillance and clearance of pathogens in the central nervous system, but evidence indicates that in Alzheimer’s disease, microglial function is compromised, and this contributes to the pathology. It is unclear what factors cause the inappropriate activation of the microglia in Alzheimer’s disease, but one contributor may be infiltrating peripheral immune cells and these include macrophages and T cells. It has been suggested that both cell types modulate the phenotype of microglia, highlighting the importance of crosstalk between the innate and adaptive immune system in Alzheimer’s disease. This review outlines our current knowledge of how cells of the peripheral immune system, specifically macrophages and T cells, may modulate microglial phenotype in the context of Alzheimer’s disease and considers the impact on their function, especially phagocytic capacity.
Immunization with current acellular pertussis (aP) vaccines protects against severe pertussis, but immunity wanes rapidly after vaccination and these vaccines do not prevent nasal colonization with Bordetella pertussis. Studies in mouse and baboon models have demonstrated that Th1 and Th17 responses are integral to protective immunity induced by previous infection with B. pertussis and immunization with whole cell pertussis (wP) vaccines. Mucosal Th17 cells, IL-17 and secretory IgA (sIgA) are particularly important in generating sustained sterilizing immunity in the nasal cavity. Current aP vaccines induce potent IgG and Th2-skewed T cell responses but are less effective at generating Th1 and Th17 responses and fail to prime respiratory tissue-resident memory T (TRM) cells, that maintain long-term immunity at mucosal sites. In contrast, a live attenuated pertussis vaccine, pertussis outer membrane vesicle (OMV) vaccines or aP vaccines formulated with novel adjuvants do induce cellular immune responses in the respiratory tract, especially when delivered by the intranasal route. An increased understanding of the mechanisms of sustained protective immunity, especially the role of respiratory TRM cells, will facilitate the development of next generation pertussis vaccines that not only protect against pertussis disease, but prevent nasal colonization and transmission of B. pertussis.
Current COVID-19 vaccines prevent severe disease, but do not induce mucosal immunity or prevent infection with SARS-CoV-2, especially with recent variants. Furthermore, serum antibody responses wane soon after immunization. We assessed the immunogenicity and protective efficacy of an experimental COVID-19 vaccine based on the SARS-CoV-2 Spike trimer formulated with a novel adjuvant LP-GMP, comprising TLR2 and STING agonists. We demonstrated that immunization of mice twice by the intranasal (i.n.) route or by heterologous intramuscular (i.m.) prime and i.n. boost with the Spike-LP-GMP vaccine generated potent Spike-specific IgG, IgA and tissue-resident memory (TRM) T cells in the lungs and nasal mucosa that persisted for at least 3 months. Furthermore, Spike-LP-GMP vaccine delivered by i.n./i.n., i.m./i.n., or i.m./i.m. routes protected human ACE-2 transgenic mice against respiratory infection and COVID-19-like disease following lethal challenge with ancestral or Delta strains of SARS-CoV-2. Our findings underscore the potential for nasal vaccines in preventing infection with SARS-CoV-2 and other respiratory pathogen.
Tissue‐resident memory T (T RM ) cells play a key role in sustained protective immunity against Bordetella pertussis infection of the nasal mucosa. Current alum‐adjuvanted acellular pertussis (aP) vaccines protect against severe pertussis disease but fail to prevent nasal infection with B. pertussis . Here we demonstrate that immunization of mice with an aP vaccine failed to generate respiratory T RM cells, but did induce antigen‐specific CD4 + Treg cells that expressed Foxp3, CD49b, PD‐1 and LAG‐3, and CD8 + Treg cells that expressed CD122, PD‐1, and IL‐10. B. pertussis ‐specific CD4 + and CD8 + T cell lines established from aP‐immunized mice expressed the regulatory markers and suppressed activation of Th1 and Th17 cells. Blockade of IL‐10 signaling during aP immunization or B. pertussis challenge promoted the induction of IL‐17‐secreting CD4 + T RM responses and enhanced bacterial clearance from the nose. Addition of the adjuvant LP‐GMP, comprising TLR2 and STING agonists, to the aP vaccine and delivery by the nasal route promoted the induction of antigen‐specific IL‐17‐producing CD4 + T RM cells and enhanced vaccine efficacy. Our findings demonstrate that aP vaccines suppress the induction of protective T RM cells in part through the induction of CD4 + and CD8 + Treg cells, which can be overcome using a potent adjuvant and delivery of the vaccine intranasally.
Whooping cough (pertussis) remains a global health problem despite widespread vaccination. Infection with Bordetella pertussis induces tissue-resident memory CD4 T cells (TRM) with Th1/Th17 phenotype, which confer protective immunity against re-infection. Current alum-adjuvanted acellular pertussis (aP) vaccines (aP/alum) protect against lung infection but induce limited cellular immunity or expansion of respiratory TRM cells and fail to prevent infection of the nasal mucosa or bacterial transmission. This study aims to elucidate the mechanisms by which aP/alum vaccines fail to recruit TRM cells to the nasal tissue and how novel adjuvants may overcome this deficit. Immunization of mice with aP/alum vaccine induced antibody responses but failed to induce systemic Th1 or Th17 responses and TRM cells in nasal tissue after B. pertussis challenge. In contrast, immunization of mice with aP/alum vaccine induced IL-10 production in draining lymph nodes. Immunization of IL-10-deficient mice with an aP/alum vaccine promoted induction of respiratory IFN-γ and IL-17-secreting TRM cells and conferred protection against B. pertussis infection of the nasal cavity. Substitution or adding a novel adjuvant LP-GMP, comprising TLR2 and STING agonists, to an aP vaccine generated respiratory TRM cells and promoted bacterial clearance from the nasal mucosa. These findings suggest that IL-10 may play a role in the failure of aP/alum vaccines to protect against B. pertussis infection of the nasal mucosa by suppressing activation and recruitment of TRM cells, but this can be overcome by adding the potent adjuvant LP-GMP to the aP/alum vaccine formulation.